In what is being seen as the opening foray of a crackdown on the opioid epidemic, the FDA has sent a warning letter to drug distributor McKesson. The federal agency has accused the company of shipping “illegitimate” products, specifically failing to identify, quarantine, or investigate shipments that had been tampered with. (CNBC)

Healthcare outpaced other business segments in Q4 at agency holding company Omnicom Group. Healthcare revenue was up 7.6% in Q4, and increased by 4.5% for all of 2018. However, the holding company’s overall revenue was down 2.2% to $4.1 billion in Q4 and up 0.1% for all of 2018 to $15.3 billion. (Omnicom) Omnicom’s Q4 numbers beat analysts’ expectations. (Reuters)

The Centers for Disease Control and Prevention has blamed the e-cigarette industry for a spike in teen tobacco use. The CDC found the number of high-school students who used tobacco products, including e-cigarettes, increased by 38% over the course of a year. (CNBC)

Merck reported positive results from late-stage trials of a combination of its cancer immunotherapy Keytruda with Pfizer’s Inlyta. The combo reduced the risk of death by 47% for patients with the most common form of kidney cancer in comparison with treatment by chemo drug Sutent. (Reuters)

What do the FDA’s plans for stepped-up monitoring of dietary supplement marketing mean for the industry? For one, the FDA is planning to continue to monitor dietary supplements more like foods than drugs, FDA Commissioner Scott Gottlieb said. Instead, the federal agency is responding to criticism that it has not stopped supplements from containing drugs or being marketed like them. (Associated Press)